Pretax income is the income that a company earns before paying income taxes. Cogent Biosciences's pretax income for the
three
months ended in Dec. 2023 was $-54.37 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-192.41 Mil.
Cogent Biosciences's pretax margin was %.
During the past 9 years, Cogent Biosciences's highest Pretax Margin was -141.49%. The lowest was -950.43%. And the median was -295.06%.
Cogent Biosciences Pre-Tax Income Historical Data
The historical data trend for Cogent Biosciences's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cogent Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences Pre-Tax Income Distribution
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's Pre-Tax Income falls into.
Cogent Biosciences Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Cogent Biosciences's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-192.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (NAS:COGT) Pre-Tax Income Explanation
Cogent Biosciences's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 9 years, Cogent Biosciences's highest Pretax Margin was -141.49%. The lowest was -950.43%. And the median was -295.06%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Cogent Biosciences's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Cogent Biosciences (Cogent Biosciences) Business Description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COGT has been successfully added to your 